Bioventus Reaches Milestone with DUROLANE Worldwide

Bioventus DUROLANE

Bioventus reports two million treatments globally with DUROLANE® single-injection hyaluronic acid (HA) product used to treat knee osteoarthritis (OA) pain.

DUROLANE has more clinical studies than any other U.S. single-injection HA, and has shown in studies to provide greater reduction in OA knee pain vs. Sanofi Genzyme's Synvisc-One®.

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us